Neumora Therapeutics, Inc. reported a net loss of $120.7 million for the six months ended June 30, 2025, compared to a net loss of $112.4 million for the same period in 2024. The company's total operating expenses increased slightly to $125.0 million from $123.9 million year-over-year. Research and development expenses decreased by 4% to $90.9 million, primarily due to reduced costs associated with the navacaprant program, which saw a decline of $3.1 million. General and administrative expenses rose by 16% to $34.1 million, driven by higher personnel-related costs and stock-based compensation.
In terms of liquidity, Neumora reported cash, cash equivalents, and marketable securities totaling $217.6 million as of June 30, 2025, down from $290.7 million at the end of 2024. The decrease in cash reserves was attributed to significant cash outflows from operating activities, which totaled $111.9 million for the first half of 2025. The company has not generated any revenue from product sales and continues to rely on external financing to support its operations, including a recent term loan agreement with K2 HealthVentures LLC that provides up to $125 million in funding.
Strategically, Neumora is advancing its clinical pipeline, which includes seven programs targeting various neuropsychiatric disorders. The company is currently conducting a Phase 3 trial for navacaprant, aimed at treating major depressive disorder, and a Phase 1b study for NMRA-511, which targets agitation associated with Alzheimer's disease. The company has also made significant investments in research and development, with a focus on enhancing its precision neuroscience approach.
Operationally, Neumora's employee headcount has fluctuated, reflecting changes in its research and development strategy. The company has also engaged in various asset acquisitions to bolster its pipeline, including agreements with Amgen and Vanderbilt University for exclusive rights to develop certain compounds. As of June 30, 2025, Neumora's accumulated deficit stood at $1.07 billion, highlighting the financial challenges faced as it seeks to bring its product candidates to market.
Looking ahead, Neumora anticipates continued operating losses as it invests in clinical trials and product development. The company expects to require additional capital to fund its operations and pursue its long-term business objectives, including the potential commercialization of its product candidates. Neumora's management remains focused on advancing its clinical programs while navigating the complexities of the biopharmaceutical landscape.
About Neumora Therapeutics, Inc.
Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for brain diseases. Its pipeline includes programs targeting neuropsychiatric and neurodegenerative disorders, such as depression, dementia-related agitation, schizophrenia, ALS, and Parkinson’s disease. The company leverages novel mechanisms, AI-driven precision neuroscience, and proprietary compounds to address unmet medical needs in mental health and neurodegeneration.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.